Predicting GLP-1 Discontinuation From Pharmacy Claims
Published: | Updated:
|Articles|June 1, 1999
Supplements and Featured Publications
- Clinical and Economic Impact of Breast Cancer Treatment and Prevention in High-Risk Women
- Volume 5
- Issue 6 Suppl
Overview of Cancer Economics
Author(s)C. Daniel Mullins, PhD
Advertisement
Articles in this issue
over 27 years ago
Participating Facultyover 27 years ago
Benefits Foregone: Too Much of the Wrong and Too Little of the Rightover 27 years ago
Breast Cancer Epidemiology: An Overviewover 27 years ago
Breast Cancer Stage Cost Analysis in a Managed Care Populationover 27 years ago
Question-and-Answer Sessionover 27 years ago
Selected AbstractsAdvertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
5 August FDA Approvals Marked by Novelty, Pushback
2
Newer Agents, New Advantages: Brexpiprazole, Cariprazine, and Lumateperone in MDD
3
Dosing, Tolerability, and Formulary Impact: Aripiprazole and Quetiapine XR in MDD
4
Cross-Trial Vitiligo Data: What Payers Can and Can't Compare
5